Familial Cancer Clinical Unit

Home | Research & Innovation | Scientific Programmes | Human Cancer Genetics Programme | Familial Cancer Clinical Unit

Staff Scientists

  • Ana Osorio

Graduate Students

  • Erik Michel Marchena

Technicians

  • Alicia Barroso
  • Victoria Fernández
  • Verónica García
  • Fátima Mercadillo

The SARS-CoV2 pandemic created an unprecedented situation affecting all human activities and it forced alliances between healthcare workers, academics, scientists, and administrative and government entities around the world, to accelerate our knowledge about the disease and the search for efficient treatments and immunisation. COVID-19 exhibits great clinical and, possibly, populational heterogeneity, in which our genes probably play an important role.

In April 2020, our Unit, together with the Genotyping Unit, set out to identify prognostic markers that could help to stratify the population and allow us to identify a priori those subjects who will have a more severe course of Covid-19. Understanding this would enable us to focus preventive resources on them and prioritise future immunisation. Since the beginning of the pandemic, various national and international projects and initiatives have been launched with similar objectives. The COVID-19 Host Genetics Initiative (https://www.covid19hg.org/) is an international consortium that integrates more than 150 participants. Together with other groups from Spain, we are participating in exploring the role of host genetic factors in the severity of the disease. At the national level, the ScourGe consortium was created, made up of more than 70 clinical, research and biobank groups. We are currently analysing the genome of more than 10,000 individuals with different clinical forms of Covid-19.

The goal is to ultimately gather genomic data from many thousands of individuals from different populations to try to identify clinically relevant markers in a disease like Covid-19, whose genetic bases will be difficult to unravel.

Publications

Up